Boston, MA -- (SBWIRE) -- 10/17/2012 -- The Big Pharma Peer set - comprising those companies with annual revenues in excess of $10bn - posted H1 2012 sales of $196.6bn, down by $4.2bn over the total for H1 2011. Of the 12 companies covered in this analysis, half posted positive H1 2012 sales growth (over H1 2011) others were not so fortunate.

Scope
- Comparative performance of leading branded prescription pharmaceutical companies
- Snapshot of Big Pharma's current sales performance and outlook through to 2017

Highlights

French company Sanofi saw the biggest advance in H1 2012 sales (over the year prior). The company enjoyed pharmaceutical sales growth from a range of products, but the biggest cause for the upturn in sales was Sanofi's reporting a full half year of Genzyme-sourced products.

View Full Report Details and Table of Contents

Both AstraZeneca and Pfizer posted the biggest H1 2012 sales losses compared to H1 2011, seeing their sales decline by $2.7bn each over the year prior. For both companies, generic sales erosion of flagship products was the primary cause of the sales deficit.

Reasons to Get this Report
- Analyze the current and forecast performance of the Big Pharma peer set as a whole through a variety of key metrics
- Company-by-company analysis of performance through the first six months of 2012 and outlook for the future

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Bayer HealthCare Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- A.P. Pharma, Inc. (APPA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Alliance Pharma Plc (APH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Elan Corporation, plc (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bristol-Myers Squibb Company (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Dainippon Sumitomo Pharma Co., Ltd. (4506) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Acceleron Pharma, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Bioniche Life Sciences, Inc. (BNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- BioCryst Pharmaceuticals, Inc. (BCRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Agenix Limited (AGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile